4.
Prognostic factors | Univariate | Multivariate | |||||
HR | 95% CI | P | HR | 95% CI | P | ||
OS, overall survival; BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma; AC, adenocarcinoma; ASC, adenosquamous carcinoma; LNM, lymph node metastasis; LVSI, lymphovascular space invasion; HR, hazard ratio; 95% CI, 95% confidence interval. | |||||||
Age at diagnosis (year) (≥45 vs. <45) | 1.034 | 0.576–1.854 | 0.912 | – | – | – | |
BMI (kg/m2) (≥24 vs. <24) | 0.949 | 0.528–1.705 | 0.861 | – | – | – | |
FIGO stage (Ib vs. IIa) | 1.057 | 0.509–2.195 | 0.882 | – | – | – | |
Tumor size (cm) (≤4 vs.>4) | 0.890 | 0.490–1.618 | 0.703 | – | – | – | |
Histology (SCC vs.AC vs. ASC) | 1.165 | 0.460–2.952 | 0.747 | – | – | – | |
Differentiation (G1–G2 vs. G3) | 0.317 | 0.169–0.596 | 0.000 | 0.469 | 0.245–0.896 | 0.022 | |
LNM (+ vs. –) | 7.809 | 4.300–14.181 | 0.000 | 5.117 | 2.725–9.610 | 0.000 | |
Stromal invasion (≥1/2 vs. <1/2) | 1.760 | 0.969–3.199 | 0.060 | – | – | – | |
LVSI (+ vs. –) | 5.622 | 3.111–10.162 | 0.000 | 3.054 | 1.620–5.755 | 0.001 |